Mechanism of Action
Inhibits NF-kB nuclear translocation and downstream pro-inflammatory cytokine production without melanocortin receptor-mediated side effects.
Clinical Use
No approved use. ZERO human clinical trials. Research use only.
Contraindications
No established contraindications due to lack of clinical data.
Evidence Summary
ZERO human clinical trials. NF-kB pathway IBD mouse model data only. No human PK/bioavailability data.
Key Studies
- 1.IBD mouse models 2015-2022 — reduced colonic inflammation, disease severity, and inflammatory cytokine production via NF-kB pathway inhibition. Preclinical
Evidence Gaps
ZERO human clinical trials. No human PK/bioavailability data. Manufacturing and purity standards not established.
Emerging Research
Growing clinical interest for oral IBD applications. Potential complementary use with BPC-157 for gut healing.